23andMe said it's started exploring strategic alternatives, including a possible sale. The company released third-quarter ...

The DNA-testing company is exploring its options, including a business combination and the sale of some or all of its assets.

A pioneer in genetic heritage services, 23andMe has seen much of its share price wiped out in the past year as it struggles ...

SUNNYVALE, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics company with a mission to help ...

Me (ME) forms special board committee to explore strategic alternatives, including sale, restructuring, or business ...

By the 2023 fiscal year, 23andMe had reported a net loss of $312 million and its individual share price has plummeted a ...

23andMe Holding Co. ( ME, Financials) announced that its board's Special Committee is reviewing strategic alternatives, ...

Company Notes Continued Concerns Regarding Liquidity and Consideration of Potential Ways to Address Operational and Financial ...

At-home DNA testing is no longer in high demand — and critics have raised concerns about unreliable tests and privacy.

23andMe said it's started exploring strategic alternatives, including a possible sale. The company released third-quarter results that showed an 8% drop in consumer services revenue year over year.

The struggling genetic-testing company 23andMe has been quietly exploring a possible sale of its telehealth offering, Business Insider has learned. 23andMe has been testing the waters for a buyer ...